Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 22, 2003

View Archived Issues

Adenosine alleviates neuropathic pain in humans

Advantages for insulin/metformin vs. triple oral therapy in type 2 diabetes

Pentostatin in children with chronic GVHD

HDAC inhibitors reported to be potentially useful in controlling cardiac hypertrophy

Antiinflammatory effects described for IS-741 in a rat model of IBD

AVI BioPharma cleared to begin phase Ib trial of West Nile virus antisense drug

Abbott and Millennium end research alliance

Health Canada approves Gamunex

SuperGen discusses Orathecin rolling NDA submission plans with FDA

Genta to acquire Salus Therapeutics

Preliminary results of North American Cystistat trial for interstitial cystitis

Corixa and Apovia enter RC-529 agreement

Engitech to commercialize and market Alferon N in the U.S.

ImClone submits Erbitux BLA

Substance P-derived peptides with NK1-antagonist activity and their use as antitumor agents

Quinazoline-based fungal efflux pump inhibitors newly developed at Essential Therapeutics

Eisai claims novel proteasome inhibitors with utility as antitumor agents

Novel PPARalpha agonists under study at Sigma-Tau

New MMP inhibitors in early development at Leo Pharma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 28, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 28, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...